0709 203000 - Nairobi 0709 983000 - Kilifi
0709 203000 - NRB 0709 983000 - Kilifi
0709 203000 - NRB | 0709 983000 - Kilifi

Back Home

Philip Bejon/Vaccine


7 results

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.Kangoye DT Mensah VA Murungi LM Nkumama I Nebie I Marsh K Cisse B Bejon P Osier FH Sirima SB Mvvc Infant Immunology Study Group
Vaccine, (2016). 34:160-6

A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Murungi LM Kamuyu G Lowe B Bejon P Theisen M Kinyanjui SM Marsh K Osier FH
Vaccine, (2013). 31:3936-42

Response to "Poor control vaccines in two randomised trials of malaria vaccine?".Bejon P Abdulla S Lusingu J Olotu A Leach A Lievens M Tanner M von Seidlein L
Vaccine, (2009). 27:4745-6

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.Dudareva M Andrews L Gilbert SC Bejon P Marsh K Mwacharo J Kai O Nicosia A Hill AV
Vaccine, (2009). 27:3501-4

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.Agak GW Bejon P Fegan G Gicheru N Villard V Kajava AV Marsh K Corradin G
Vaccine, (2008). 26:1963-71

Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria.Bejon P Mwangi T Lowe B Peshu N Hill AV Marsh K
Vaccine, (2007). 25:8198-202

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.Bejon P Mwacharo J Kai OK Todryk S Keating S Lang T Gilbert SC Peshu N Marsh K Hill AV
Vaccine, (2006). 24:4709-15